Skip to main content Back to Top
Advertisement

5/17/2016

Aripiprazole Oral Disintegrating Tablets

Products Affected - Description

    • Abilify Discmelt oral disintegrating tablet, Otsuka America Pharmaceuticals, 10 mg, 30 count, NDC 59148-0640-23
    • Abilify Discmelt oral disintegrating tablet, Otsuka America Pharmaceuticals, 15 mg, 30 count, NDC 59148-0641-23

Reason for the Shortage

    • Otsuka has discontinued Abilify Discmelt oral disintegrating tablets. The company has also discontinued the oral solution and injection.
    • Trigen introduced aripiprazole oral disintegrating tablets in 2016.
    • Abilify oral tablets and generic aripiprazole oral tablets are not affected.

Available Products

    • Aripiprazole oral disintegrating tablet, Trigen, 10 mg, 30 count, NDC 13811-0692-30
    • Aripiprazole oral disintegrating tablet, Trigen, 15 mg, 30 count, NDC 13811-0693-30

Estimated Resupply Dates

    • All marketed presentations are available.

Updated

Updated May 17, 2016 by Leslie Jensen, PharmD, Drug Information Specialist. Created July 17, 2015 by Leslie Jensen, PharmD, Drug Information Specialist. Copyright 2017, Drug Information Service, University of Utah, Salt Lake City, UT.

Disclaimer

Drug Shortage Bulletins are copyrighted by the Drug Information Service of the University of Utah and provided by ASHP as its exclusive authorized distributor. ASHP and the University of Utah make no representations or warranties, express or implied, including, but not limited to, any implied warranty of merchantability and/or fitness for a particular purpose, with respect to such information, and specifically disclaim all such warranties. Users of this information are advised that decisions regarding the use of drugs and drug therapies are complex medical decisions and that in using this information, each user must exercise his or her own independent professional judgment. Neither ASHP nor the University of Utah assumes any liability for persons administering or receiving drugs or other medical care in reliance upon this information, or otherwise in connection with this Bulletin. Neither ASHP nor the University of Utah endorses or recommends the use of any particular drug. Any application of this information for any purpose shall be limited to personal, non-commercial use.

« Back to Drug Shortage Product Bulletins


ahfs logo

Subscribe to AHFS Clinical Drug Information to get direct access to integrated drug shortages content, plus comprehensive and actionable drug information.